TruSight Oncology 500 ctDNA
(TSO500 ctDNA)
Minimally invasive, pan-cancer next-generation sequencing assay for biomarker identification and comprehensive genomic profiling across 523 genes
TruSight Oncology 500 ctDNA
(TSO500 ctDNA)
Minimally invasive, pan-cancer next-generation sequencing assay for biomarker identification and comprehensive genomic profiling across 523 genes
Get in Touch
Our Locations
A Hybrid-Capture Approach for Target Enrichment of 523 Genes Across Various Tumor Types
Gain an expansive view of your liquid biopsy samples by targeting 523 cancer-related genes using the TruSight Oncology 500 ctDNA assay. Not only does this assay identify all relevant variants (DNA fusions, SNVs, CNVs, insertions, and deletions) across various tumor types, but it also reports tumor mutational burden (TMB) and microsatellite instability (MSI) scores.
Our comprehensive genomic panel has advantages over individual biomarker assays in its ability to detect multiple biomarkers with one test, saving time, money, and samples. Q2 Solutions can meet your profiling needs by leveraging trusted technology from Illumina® in combination with our global laboratory network and expert support team.
Minimal input, extensive results
Obtain full exon coverage of 522 out of 523 genes using as little as 3 mL of plasma, 20-30 ng of cfDNA, or 10 mL of whole blood. TSO500 ctDNA can detect biomarkers without the need of a matched normal sample.
Simple, cost-effective workflow
Detect multiple biomarkers with a single assay to save time, money, and samples. The distributable kit enables global implementation.
Confident variant detection
Obtain a high-resolution view of variants enabled by TSO500 ctDNA’s hybrid-capture chemistry and unique molecular indices (UMIs).
Measurement of key immuno-oncology biomarkers
Gain insight into TMB score and MSI score in addition to variant calls. TruSight Oncology 500 ctDNA can reproducibly assess TMB.
Expansive services enabled by our global network
Our centralized, scientific operational oversight combined with our global laboratory footprint enable comprehensive, large-scale trial support. We enable clinical development support irrespective of geography.
Flexible customization to satisfy specific needs
We work with you to understand your specific needs, and our team provides cost-effective recommendations from custom assay development to specialized bioinformatics support.
TSO500 Assay Comparison
Deep Sequencing Enabled by Q2 Solutions’ Subject Matter Expertise
Feel confident in your results with the trusted Illumina® software pipeline. Our software teams validate the most up-to-date software to ensure you are receiving optimal results. Q2 Solutions can develop custom reporting and filtering to meet your specific research needs. Q2 Solutions was one of the earliest adopters of DRAGEN™. Our technical support teams help you understand your deep sequencing data with our superior bioinformatics knowledge.
Supporting Studies Around the World
Our centralized, scientific, and operational oversight combined with our global laboratory footprint enables comprehensive, large-scale trial support. You will be supported every step of the way by our scientific project management team who will work with you to understand the most cost-effective recommendations to meet your specific needs. We are committed to transparency so you can feel confident in our promises of quality and timely delivery. We can expert support team can meet your research needs from nearly anywhere in the world with our genomic centers in the United States, China, United Kingdom, and Singapore.
Simplify Your Work
